Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

CONCLUSIONS: Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.PMID:37058234 | DOI:10.1158/1078-0432.CCR-22-3832

Source: Clinical Prostate Cancer - April 14, 2023 Category: Cancer & Oncology Authors: Emmanuel S Antonarakis Sumit K Subudhi Christopher M Pieczonka Lawrence I Karsh David I Quinn Jason M Hafron Helen M Wilfehrt Matthew Harmon Nadeem A Sheikh Neal D Shore Daniel P Petrylak Source Type: research